Qi Che, MD
Nephrology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 23
- 6 carriers
- Office
- 1
- Since medical school
- 30 years
- Graduated 1996
Offices
1 location · West Coast Kidney · 56 clinicians in this group
Hospitals listed: 052845 · 552672 · 552699 · Eden Medical Center · Highland Hospital · St Rose Hospital · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
23 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Che’s office at (510) 745-8187 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
23 of 23 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A108175 · Current
Licensed to practise in California · since 2009 · expires 2027-06-30 · Hunan Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Nephrology
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
- St Rose HospitalHayward, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency departmentPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
See every measure and the patient survey for St Rose Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 3 the same, 2 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 227 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.57 to 1.47) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 11 · 57 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.2 · 62 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 20.6 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 567 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.09 to 0.54) · 1,834 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,870 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.71 (1.17 to 6.25) · 285 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.13 (0.4 to 3.87) · 124 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.23 (0.53 to 3.92) · 295 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.87 (1.85 to 21.89) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.19 (0.86 to 9.51) · 120 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.27) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.36 (0 to 1.39) · 1,264 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 97 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.563 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 120 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35 · 116 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 29.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.8 · 147 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 101 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
What patients said (389 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$299,498
Medicare paid this office $299,498 for 568 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 31 | $80,175 | $313 |
| Long return visit (40+ min) | 170 | $53,208 | $150 |
| Home dialysis services per month (20 years or older) | 13 | $30,691 | $254 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 155 | $25,890 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 136 | $25,254 | $104 |
See all 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 31 | $80,175 | $313 |
| Long return visit (40+ min) | 170 | $53,208 | $150 |
| Home dialysis services per month (20 years or older) | 13 | $30,691 | $254 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 155 | $25,890 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 136 | $25,254 | $104 |
| Return visit (30+ min) | 153 | $25,067 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 101 | $16,636 | $147 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 239 | $6,856 | $14 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 24 | $5,328 | $59 |
| New patient visit (45+ min) | 33 | $4,599 | $139 |
| Hemodialysis procedure with physician evaluation | 46 | $3,813 | $63 |
| Transitional care management services for problem of high complexity | 13 | $3,807 | $272 |
| New patient visit (60+ min) | 20 | $3,549 | $177 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 24 | $2,898 | $46 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | $999 | $50 |
Who their Medicare patients are
568 Original Medicare patients in 2024. Average age 77 · Under 65 10% · 85 and older 28% · Women 52% · Also on Medicaid 73% · Health risk score 3.90. At or below the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 73% · Coronary heart disease 52% · Heart failure 50% · Atrial fibrillation 32% · COPD 25% · Dementia 24% · Depression 20% · Stroke 20% · Cancer 14%.
The office billed $810,017, Medicare allowed $397,175 and paid $299,498; for 2,622 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 568 | 2,622 | 77 | 3.90 | $810,017 | $299,498 |
| 2023 | 531 | 1,927 | 77 | 3.65 | $732,814 | $269,078 |
| 2022 | 523 | 1,997 | 76 | 4.00 | $700,983 | $242,987 |
| 2021 | 399 | 1,623 | 74 | 4.14 | $636,809 | $249,889 |
| 2020 | 412 | 1,738 | 73 | 4.08 | $579,090 | $221,333 |
| 2019 | 465 | 2,097 | 74 | 4.16 | $657,928 | $248,587 |
| 2018 | 433 | 1,890 | 72 | 4.09 | $599,887 | $226,384 |
| 2017 | 466 | 1,899 | 74 | 4.28 | $559,475 | $212,077 |
| 2016 | 410 | 1,889 | 72 | 4.51 | $531,339 | $217,510 |
| 2015 | 436 | 2,095 | 73 | 4.49 | $575,274 | $237,245 |
| 2014 | 424 | 2,024 | 73 | 4.36 | $605,930 | $242,806 |
| 2013 | 428 | 2,202 | 73 | 4.62 | $605,689 | $251,104 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 35 | $77,704 | $320 |
| Home dialysis services per month (20 years or older) | 16 | $36,285 | $267 |
| Long return visit (40+ min) | 142 | $29,746 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 172 | $28,281 | $72 |
| Return visit (30+ min) | 158 | $28,034 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $27,000 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $13,059 | $157 |
| New patient visit (45+ min) | 39 | $5,614 | $144 |
| New patient visit (60+ min) | 28 | $5,427 | $194 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $4,881 | $271 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,081 | $114 |
| Hemodialysis procedure with physician evaluation | 34 | $2,970 | $65 |
2022: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 37 | $70,580 | $310 |
| Home dialysis services per month (20 years or older) | 14 | $35,209 | $261 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 193 | $32,439 | $64 |
| Return visit (30+ min) | 163 | $29,138 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 111 | $18,543 | $92 |
| Long return visit (40+ min) | 94 | $12,618 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 88 | $11,080 | $122 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $7,832 | $261 |
| Hemodialysis procedure with physician evaluation | 57 | $6,241 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,088 | $174 |
| New patient visit (45+ min) | 24 | $3,201 | $133 |
| New patient visit (60+ min) | 12 | $2,459 | $205 |
| Telephone medical discussion with physician, 5-10 minutes | 27 | $1,091 | $36 |
2021: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 35 | $86,064 | $326 |
| Long return visit (40+ min) | 120 | $38,427 | $151 |
| Home dialysis services per month (20 years or older) | 13 | $29,697 | $265 |
| Return visit (30+ min) | 141 | $27,546 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $21,676 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $12,314 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 70 | $9,338 | $123 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 15 | $6,600 | $275 |
| Hemodialysis procedure with physician evaluation | 44 | $4,354 | $65 |
| New patient visit (45+ min) | 21 | $3,094 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,531 | $181 |
| New patient visit (60+ min) | 11 | $2,130 | $194 |
2020: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 45 | $78,316 | $261 |
| Long return visit (40+ min) | 148 | $32,930 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 128 | $25,340 | $66 |
| Home dialysis services per month (20 years or older) | 14 | $19,639 | $221 |
| Return visit (30+ min) | 119 | $16,505 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $14,870 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 83 | $12,185 | $126 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $4,479 | $224 |
| Hemodialysis procedure with physician evaluation | 39 | $4,036 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,729 | $178 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,671 | $104 |
| Short return visit (20+ min) | 15 | $1,074 | $72 |
2019: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 45 | $80,122 | $254 |
| Long return visit (40+ min) | 180 | $52,738 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 152 | $30,378 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 122 | $23,803 | $90 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 98 | $12,743 | $120 |
| Return visit (30+ min) | 89 | $9,748 | $86 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $6,142 | $212 |
| Hemodialysis procedure with physician evaluation | 45 | $5,202 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,363 | $177 |
| New patient visit (45+ min) | 18 | $2,581 | $143 |
| Advance care planning, first 30 minutes | 11 | $847 | $77 |
| Injection of drug or substance under skin or into muscle | 12 | $525 | $15 |
2018: 10 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $82,242 | $252 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 154 | $29,171 | $64 |
| Long return visit (40+ min) | 130 | $28,721 | $132 |
| Return visit (30+ min) | 150 | $22,211 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 94 | $19,411 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 88 | $11,589 | $117 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 18 | $4,744 | $216 |
| New patient visit (45+ min) | 30 | $4,084 | $136 |
| Hemodialysis procedure with physician evaluation | 39 | $3,987 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,923 | $172 |
2017: 10 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 42 | $69,261 | $247 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 190 | $37,697 | $63 |
| Return visit (30+ min) | 165 | $31,191 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 112 | $21,912 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 72 | $9,419 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,338 | $174 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 20 | $5,499 | $204 |
| Hemodialysis procedure with physician evaluation | 42 | $4,594 | $63 |
| Long return visit (40+ min) | 27 | $4,367 | $121 |
| New patient visit (45+ min) | 30 | $3,619 | $121 |
2016: 9 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $71,950 | $246 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 157 | $35,793 | $62 |
| Return visit (30+ min) | 158 | $31,318 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 130 | $27,536 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $17,679 | $89 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 18 | $5,642 | $209 |
| New patient visit (45+ min) | 36 | $4,723 | $131 |
| Hemodialysis procedure with physician evaluation | 43 | $4,246 | $62 |
| Long return visit (40+ min) | 19 | $3,811 | $119 |
2015: 9 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 49 | $88,586 | $247 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 181 | $39,520 | $62 |
| Return visit (30+ min) | 162 | $32,702 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 122 | $25,305 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $21,627 | $90 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 18 | $4,808 | $209 |
| Hemodialysis procedure with physician evaluation | 42 | $4,672 | $62 |
| New patient visit (45+ min) | 30 | $4,256 | $142 |
| Long return visit (40+ min) | 18 | $3,783 | $118 |
2014: 10 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 65 | $103,861 | $245 |
| Return visit (30+ min) | 151 | $32,512 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 159 | $28,051 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $24,506 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 109 | $22,635 | $173 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $6,572 | $205 |
| Long return visit (40+ min) | 40 | $6,534 | $121 |
| New patient visit (45+ min) | 36 | $4,676 | $130 |
| Hemodialysis procedure with physician evaluation | 40 | $4,138 | $62 |
| Manual urinalysis test with examination using microscope, non-automated | 15 | $63 | $4 |
2013: 10 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 64 | $107,312 | $245 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 177 | $30,623 | $61 |
| Return visit (30+ min) | 138 | $29,917 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 118 | $26,799 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 130 | $24,285 | $170 |
| Long return visit (40+ min) | 41 | $7,410 | $121 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $5,800 | $207 |
| Hemodialysis procedure with physician evaluation | 50 | $5,072 | $61 |
| New patient visit (45+ min) | 32 | $4,579 | $143 |
| New patient visit (60+ min) | 14 | $2,168 | $155 |
Medicaid work
$130,463 in 2024
Medicaid paid $130,463 for 1,650 billed services this clinician did in 2024, up to 47 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 314 | $46,434 |
| Long return visit (40+ min) | 396 | $31,911 |
| Return visit (30+ min) | 243 | $16,017 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 353 | $14,201 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 231 | $13,301 |
| 1ST HOSP IP/OBS HIGH 75 | 81 | $6,783 |
| New patient visit (45+ min) | 12 | $1,003 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 20 | $813 |
| 2024 | 1,650 | 8 | 47 | $130,463 |
| 2023 | 1,662 | 6 | 40 | $136,648 |
| 2022 | 1,494 | 8 | 48 | $93,042 |
| 2021 | 1,456 | 7 | 41 | $85,379 |
| 2020 | 1,459 | 6 | 53 | $66,824 |
| 2019 | 1,712 | 6 | 52 | $78,602 |
| 2018 | 1,729 | 6 | 40 | $72,090 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 331 | $60,429 |
| Long return visit (40+ min) | 348 | $31,335 |
| Return visit (30+ min) | 270 | $15,220 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 439 | $14,018 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 250 | $13,525 |
| 1ST HOSP IP/OBS HIGH 75 | 24 | $2,121 |
2022
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 329 | $50,329 |
| Return visit (30+ min) | 350 | $16,050 |
| Long return visit (40+ min) | 229 | $12,046 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 408 | $7,918 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 139 | $4,174 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $1,449 |
| End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older | 12 | $815 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 13 | $260 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 371 | $49,920 |
| Long return visit (40+ min) | 327 | $13,604 |
| Return visit (30+ min) | 309 | $11,382 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 365 | $7,332 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 58 | $2,021 |
| End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older | 12 | $874 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 14 | $245 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 375 | $33,733 |
| Long return visit (40+ min) | 323 | $13,349 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 451 | $11,157 |
| Return visit (30+ min) | 181 | $5,193 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 117 | $3,167 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 12 | $224 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 439 | $39,184 |
| Long return visit (40+ min) | 434 | $18,850 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 513 | $10,781 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 201 | $5,627 |
| Return visit (30+ min) | 113 | $3,974 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 12 | $187 |
2018
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 437 | $35,549 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 572 | $12,581 |
| Return visit (30+ min) | 289 | $10,160 |
| Long return visit (40+ min) | 209 | $9,348 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 176 | $4,106 |
| Iron sucrose injection | 46 | $346 |
Drugs they prescribed that Part D paid
$726,772
Pharmacies billed $726,772 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,615) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,866 generic and 749 brand-name prescriptions · $726,772 in drug cost · 30 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Farxiga | 237 | $184,732 | $779 |
| Rayaldee | 96 | $163,708 | $1,705 |
| Kerendia | 67 | $58,430 | $872 |
| Lokelma | 49 | $46,097 | $941 |
| Xphozah | 13 | $42,179 | $3,245 |
See all 45 drugs
| Farxiga | 237 | $184,732 | $779 |
| Rayaldee | 96 | $163,708 | $1,705 |
| Kerendia | 67 | $58,430 | $872 |
| Lokelma | 49 | $46,097 | $941 |
| Xphozah | 13 | $42,179 | $3,245 |
| Sevelamer Carbonate | 59 | $39,888 | $676 |
| Jardiance | 50 | $33,727 | $675 |
| Dapagliflozin | 36 | $27,989 | $777 |
| Invokana | 18 | $14,926 | $829 |
| Procrit | 26 | $11,844 | $456 |
| Calcium Acetate | 44 | $7,851 | $178 |
| Prosol | 49 | $6,580 | $134 |
| Calcitriol | 228 | $3,529 | $15 |
| Potassium Citrate Er | 28 | $2,851 | $102 |
| Midodrine | 13 | $2,579 | $198 |
| Febuxostat | 17 | $2,268 | $133 |
| Tacrolimus | 22 | $2,233 | $101 |
| Potassium Chloride | 41 | $1,534 | $37 |
| Lisinopril | 192 | $1,132 | $6 |
| Allopurinol | 121 | $1,086 | $9 |
| Furosemide | 246 | $986 | $4 |
| Sodium Polystyrene Sulfonate | 17 | $972 | $57 |
| Losartan | 109 | $850 | $8 |
| Tamsulosin | 56 | $639 | $11 |
| Hydralazine | 58 | $622 | $11 |
| Metoprolol | 39 | $505 | $13 |
| Losartan-Hydrochlorothiazide | 30 | $420 | $14 |
| Rosuvastatin | 11 | $376 | $34 |
| Carvedilol | 45 | $352 | $8 |
| Nifedipine Er | 15 | $346 | $23 |
| Mycophenolate Mofetil | 15 | $342 | $23 |
| Amlodipine Besylate | 103 | $297 | $3 |
| Mycophenolic Acid | 13 | $188 | $14 |
| Hydrochlorothiazide | 61 | $182 | $3 |
| Metformin | 33 | $161 | $5 |
| Metoprolol | 12 | $146 | $12 |
| Clonidine | 19 | $128 | $7 |
| Gabapentin | 13 | $118 | $9 |
| Isosorbide Dinitrate | 12 | $71 | $6 |
| Irbesartan | 13 | $66 | $5 |
| Glipizide | 12 | $43 | $4 |
| Atorvastatin | 23 | $42 | $2 |
| Oxybutynin Chloride Er | 13 | $30 | $2 |
| Lisinopril-Hydrochlorothiazide | 11 | $28 | $3 |
| Simvastatin | 11 | $21 | $2 |
Year by year
| 2024 | 2,615 | 296 | 0% (0) | 29% | $726,772 |
| 2023 | 2,262 | 284 | 0% (0) | 24% | $612,074 |
| 2022 | 1,912 | 239 | 0% (0) | 25% | $481,868 |
| 2021 | 1,999 | 225 | 0% (0) | 22% | $381,995 |
| 2020 | 2,122 | 219 | 0% (0) | 23% | $428,723 |
| 2019 | 2,104 | 221 | 0% (0) | 21% | $330,397 |
| 2018 | 2,001 | 201 | None | 15% | $246,804 |
| 2017 | 1,914 | 180 | None | None | $517,391 |
| 2016 | 2,142 | 175 | None | None | $542,672 |
| 2015 | 2,317 | 168 | None | None | $446,424 |
| 2014 | 2,203 | 165 | None | 27% | $350,055 |
| 2013 | 1,918 | 159 | 1% (14) | None | $289,620 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 39 drugs
| Farxiga | 168 | $142,680 | $849 |
| Rayaldee | 73 | $118,241 | $1,620 |
| Renvela | 26 | $54,364 | $2,091 |
| Velphoro | 16 | $45,665 | $2,854 |
| Kerendia | 42 | $39,352 | $937 |
| Lokelma | 32 | $33,141 | $1,036 |
| Sevelamer Carbonate | 41 | $27,881 | $680 |
| Auryxia | 14 | $23,156 | $1,654 |
| Procrit | 18 | $17,229 | $957 |
| Cinacalcet | 11 | $14,112 | $1,283 |
| Febuxostat | 20 | $10,013 | $501 |
| Calcitriol | 204 | $5,180 | $25 |
| Prosol | 30 | $5,062 | $169 |
| Potassium Citrate Er | 26 | $3,805 | $146 |
| Tacrolimus | 11 | $3,792 | $345 |
| Calcium Acetate | 35 | $3,546 | $101 |
| Furosemide | 282 | $2,211 | $8 |
| Losartan | 100 | $2,063 | $21 |
| Nifedipine Er | 36 | $1,772 | $49 |
| Lisinopril | 131 | $1,751 | $13 |
| Hydralazine | 61 | $1,709 | $28 |
| Allopurinol | 96 | $1,596 | $17 |
| Amlodipine Besylate | 120 | $1,584 | $13 |
| Potassium Chloride | 61 | $1,414 | $23 |
| Tamsulosin | 54 | $937 | $17 |
| Carvedilol | 34 | $807 | $24 |
| Sodium Polystyrene Sulfonate | 16 | $803 | $50 |
| Metoprolol | 28 | $628 | $22 |
| Hydrochlorothiazide | 69 | $627 | $9 |
| Losartan-Hydrochlorothiazide | 20 | $546 | $27 |
| Clonidine | 31 | $522 | $17 |
| Mycophenolate Mofetil | 15 | $518 | $35 |
| Atorvastatin | 34 | $411 | $12 |
| Metformin | 19 | $362 | $19 |
| Metoprolol | 13 | $300 | $23 |
| Gabapentin | 11 | $268 | $24 |
| Simvastatin | 14 | $138 | $10 |
| Glipizide | 16 | $122 | $8 |
| Ciprofloxacin | 12 | $79 | $7 |
2022: 38 drugs
| Renvela | 28 | $96,303 | $3,439 |
| Farxiga | 113 | $87,233 | $772 |
| Rayaldee | 37 | $70,995 | $1,919 |
| Auryxia | 19 | $25,515 | $1,343 |
| Lokelma | 29 | $24,375 | $841 |
| Sevelamer Carbonate | 31 | $22,162 | $715 |
| Invokana | 15 | $17,352 | $1,157 |
| Procrit | 28 | $16,778 | $599 |
| Veltassa | 16 | $16,440 | $1,028 |
| Prosol | 64 | $13,085 | $204 |
| Potassium Citrate Er | 28 | $6,835 | $244 |
| Calcium Acetate | 31 | $4,350 | $140 |
| Calcitriol | 154 | $3,949 | $26 |
| Sodium Polystyrene Sulfonate | 22 | $2,164 | $98 |
| Nifedipine Er | 31 | $1,713 | $55 |
| Midodrine | 14 | $1,683 | $120 |
| Allopurinol | 95 | $1,574 | $17 |
| Gentamicin Sulfate | 21 | $1,384 | $66 |
| Losartan | 96 | $1,337 | $14 |
| Furosemide | 255 | $1,329 | $5 |
| Hydralazine | 48 | $1,306 | $27 |
| Amlodipine Besylate | 91 | $1,130 | $12 |
| Lisinopril | 126 | $1,127 | $9 |
| Potassium Chloride | 35 | $802 | $23 |
| Metoprolol | 23 | $628 | $27 |
| Carvedilol | 32 | $484 | $15 |
| Clonidine | 30 | $451 | $15 |
| Losartan-Hydrochlorothiazide | 22 | $436 | $20 |
| Atorvastatin | 42 | $414 | $10 |
| Hydrochlorothiazide | 49 | $411 | $8 |
| Tamsulosin | 23 | $349 | $15 |
| Gabapentin | 21 | $325 | $15 |
| Prednisone | 34 | $265 | $8 |
| Metoprolol | 17 | $224 | $13 |
| Simvastatin | 16 | $117 | $7 |
| Amoxicillin-Clavulanate Potass | 12 | $115 | $10 |
| Amiloride | 13 | $113 | $9 |
| Metformin | 12 | $88 | $7 |
2021: 41 drugs
| Renvela | 26 | $106,872 | $4,110 |
| Rayaldee | 32 | $58,127 | $1,816 |
| Invokana | 37 | $30,259 | $818 |
| Velphoro | 12 | $24,225 | $2,019 |
| Procrit | 38 | $18,410 | $484 |
| Auryxia | 23 | $16,914 | $735 |
| Sevelamer Carbonate | 62 | $15,650 | $252 |
| Lokelma | 19 | $14,289 | $752 |
| Veltassa | 13 | $12,730 | $979 |
| Farxiga | 14 | $7,814 | $558 |
| Calcitriol | 199 | $5,296 | $27 |
| Cyclosporine Modified | 12 | $4,738 | $395 |
| Prosol | 32 | $4,669 | $146 |
| Calcium Acetate | 31 | $4,622 | $149 |
| Potassium Citrate Er | 30 | $4,578 | $153 |
| Retacrit | 16 | $4,401 | $275 |
| Allopurinol | 100 | $1,604 | $16 |
| Gentamicin Sulfate | 32 | $1,599 | $50 |
| Losartan-Hydrochlorothiazide | 45 | $1,451 | $32 |
| Amlodipine Besylate | 126 | $1,407 | $11 |
| Sodium Polystyrene Sulfonate | 25 | $1,362 | $54 |
| Nifedipine Er | 30 | $1,271 | $42 |
| Furosemide | 235 | $1,225 | $5 |
| Hydralazine | 58 | $1,113 | $19 |
| Losartan | 85 | $1,014 | $12 |
| Metoprolol | 42 | $799 | $19 |
| Lisinopril | 128 | $776 | $6 |
| Tamsulosin | 30 | $674 | $22 |
| Atorvastatin | 28 | $433 | $15 |
| Clonidine | 44 | $430 | $10 |
| Potassium Chloride | 17 | $428 | $25 |
| Enalapril Maleate | 11 | $385 | $35 |
| Spironolactone | 17 | $298 | $18 |
| Carvedilol | 22 | $284 | $13 |
| Metoprolol | 41 | $282 | $7 |
| Hydrochlorothiazide | 42 | $266 | $6 |
| Simvastatin | 21 | $179 | $9 |
| Prednisone | 19 | $165 | $9 |
| Gabapentin | 24 | $139 | $6 |
| Amiloride | 14 | $80 | $6 |
| Atenolol | 15 | $57 | $4 |
2020: 43 drugs
| Renvela | 52 | $126,001 | $2,423 |
| Rayaldee | 41 | $72,867 | $1,777 |
| Velphoro | 14 | $38,371 | $2,741 |
| Cinacalcet | 12 | $26,345 | $2,195 |
| Lokelma | 36 | $24,667 | $685 |
| Veltassa | 19 | $17,627 | $928 |
| Sevelamer Carbonate | 48 | $13,995 | $292 |
| Invokana | 16 | $12,769 | $798 |
| Retacrit | 14 | $9,519 | $680 |
| Auryxia | 17 | $8,942 | $526 |
| Intralipid | 28 | $7,120 | $254 |
| Procrit | 14 | $6,846 | $489 |
| Calcitriol | 254 | $6,220 | $24 |
| Calcium Acetate | 42 | $5,085 | $121 |
| Potassium Citrate Er | 21 | $4,364 | $208 |
| Cyclosporine Modified | 11 | $3,995 | $363 |
| Losartan-Hydrochlorothiazide | 39 | $2,497 | $64 |
| Sodium Polystyrene Sulfonate | 29 | $2,405 | $83 |
| Allopurinol | 130 | $2,079 | $16 |
| Labetalol | 16 | $1,713 | $107 |
| Nifedipine Er | 21 | $1,413 | $67 |
| Hydralazine | 59 | $1,360 | $23 |
| Amlodipine Besylate | 141 | $1,350 | $10 |
| Metoprolol | 69 | $1,281 | $19 |
| Furosemide | 201 | $1,083 | $5 |
| Gentamicin Sulfate | 27 | $1,012 | $37 |
| Losartan | 73 | $986 | $14 |
| Lisinopril | 154 | $966 | $6 |
| Mycophenolate Mofetil | 12 | $775 | $65 |
| Tamsulosin | 36 | $707 | $20 |
| Clonidine | 37 | $675 | $18 |
| Carvedilol | 40 | $473 | $12 |
| Potassium Chloride | 15 | $390 | $26 |
| Gabapentin | 23 | $352 | $15 |
| Metoprolol | 35 | $345 | $10 |
| Hydrochlorothiazide | 46 | $309 | $7 |
| Atorvastatin | 27 | $297 | $11 |
| Spironolactone | 12 | $232 | $19 |
| Simvastatin | 34 | $168 | $5 |
| Atenolol | 11 | $112 | $10 |
| Amiloride | 15 | $97 | $6 |
| Prednisone | 16 | $73 | $5 |
| Ciprofloxacin | 12 | $60 | $5 |
2019: 38 drugs
| Renvela | 43 | $67,117 | $1,561 |
| Rayaldee | 25 | $37,355 | $1,494 |
| Sevelamer Carbonate | 51 | $29,270 | $574 |
| Veltassa | 18 | $17,482 | $971 |
| Auryxia | 13 | $16,848 | $1,296 |
| Procrit | 30 | $16,267 | $542 |
| Lokelma | 21 | $15,208 | $724 |
| Prosol | 73 | $9,245 | $127 |
| Uloric | 15 | $7,769 | $518 |
| Calcitriol | 290 | $6,754 | $23 |
| Invokana | 11 | $5,549 | $504 |
| Calcium Acetate | 45 | $3,844 | $85 |
| Febuxostat | 15 | $3,212 | $214 |
| Potassium Citrate Er | 15 | $2,454 | $164 |
| Nifedipine Er | 24 | $2,252 | $94 |
| Allopurinol | 134 | $1,975 | $15 |
| Metoprolol | 80 | $1,857 | $23 |
| Labetalol | 18 | $1,466 | $81 |
| Lisinopril | 202 | $1,444 | $7 |
| Amlodipine Besylate | 126 | $1,112 | $9 |
| Furosemide | 190 | $1,039 | $5 |
| Sodium Polystyrene Sulfonate | 13 | $963 | $74 |
| Gentamicin Sulfate | 24 | $894 | $37 |
| Potassium Chloride | 26 | $721 | $28 |
| Losartan | 75 | $701 | $9 |
| Clonidine | 52 | $620 | $12 |
| Hydralazine | 38 | $569 | $15 |
| Tamsulosin | 22 | $418 | $19 |
| Losartan-Hydrochlorothiazide | 39 | $414 | $11 |
| Spironolactone | 11 | $325 | $30 |
| Hydrochlorothiazide | 57 | $255 | $4 |
| Gabapentin | 16 | $235 | $15 |
| Metoprolol | 30 | $234 | $8 |
| Atenolol | 11 | $134 | $12 |
| Simvastatin | 38 | $134 | $4 |
| Carvedilol | 17 | $130 | $8 |
| Atorvastatin | 12 | $96 | $8 |
| Glipizide | 12 | $26 | $2 |
2018: 34 drugs
| Renvela | 48 | $73,986 | $1,541 |
| Sevelamer Carbonate | 55 | $38,954 | $708 |
| Sensipar | 12 | $30,672 | $2,556 |
| Auryxia | 15 | $12,810 | $854 |
| Veltassa | 14 | $10,848 | $775 |
| Uloric | 13 | $6,949 | $535 |
| Calcitriol | 304 | $6,901 | $23 |
| Calcium Acetate | 62 | $5,853 | $94 |
| Prosol | 23 | $3,055 | $133 |
| Nifedipine Er | 45 | $2,220 | $49 |
| Labetalol | 18 | $1,513 | $84 |
| Allopurinol | 101 | $1,457 | $14 |
| Lisinopril | 242 | $1,303 | $5 |
| Amlodipine Besylate | 159 | $911 | $6 |
| Metoprolol | 34 | $720 | $21 |
| Furosemide | 159 | $713 | $4 |
| Clonidine | 59 | $647 | $11 |
| Hydralazine | 26 | $628 | $24 |
| Gentamicin Sulfate | 20 | $580 | $29 |
| Sodium Polystyrene Sulfonate | 12 | $566 | $47 |
| Potassium Chloride | 24 | $518 | $22 |
| Tamsulosin | 23 | $396 | $17 |
| Valsartan | 12 | $381 | $32 |
| Atorvastatin | 28 | $332 | $12 |
| Simvastatin | 59 | $269 | $5 |
| Losartan | 36 | $263 | $7 |
| Metoprolol | 59 | $251 | $4 |
| Losartan-Hydrochlorothiazide | 21 | $209 | $10 |
| Irbesartan | 11 | $186 | $17 |
| Gabapentin | 20 | $182 | $9 |
| Cartia Xt | 11 | $153 | $14 |
| Hydrochlorothiazide | 31 | $150 | $5 |
| Carvedilol | 11 | $127 | $12 |
| Atenolol | 12 | $95 | $8 |
2017: 32 drugs
| Renvela | 103 | $200,086 | $1,943 |
| Sensipar | 98 | $149,455 | $1,525 |
| Velphoro | 22 | $72,971 | $3,317 |
| Calcitriol | 261 | $5,662 | $22 |
| Calcium Acetate | 55 | $5,280 | $96 |
| Zetia | 12 | $3,751 | $313 |
| Uloric | 12 | $3,618 | $301 |
| Sps | 13 | $2,315 | $178 |
| Labetalol | 33 | $2,225 | $67 |
| Nifedipine Er | 34 | $1,627 | $48 |
| Allopurinol | 109 | $1,395 | $13 |
| Hydralazine | 35 | $1,119 | $32 |
| Amlodipine Besylate | 183 | $1,026 | $6 |
| Lisinopril | 189 | $912 | $5 |
| Metoprolol | 42 | $859 | $20 |
| Gentamicin Sulfate | 19 | $590 | $31 |
| Clonidine | 60 | $580 | $10 |
| Valsartan | 12 | $522 | $44 |
| Tamsulosin | 29 | $470 | $16 |
| Furosemide | 97 | $427 | $4 |
| Atorvastatin | 33 | $427 | $13 |
| Potassium Chloride | 19 | $424 | $22 |
| Simvastatin | 44 | $271 | $6 |
| Losartan | 35 | $246 | $7 |
| Pravastatin | 20 | $239 | $12 |
| Metoprolol | 62 | $236 | $4 |
| Levothyroxine | 12 | $212 | $18 |
| Spironolactone | 11 | $197 | $18 |
| Gabapentin | 22 | $160 | $7 |
| Hydrochlorothiazide | 16 | $146 | $9 |
| Omeprazole | 20 | $104 | $5 |
| Glipizide | 13 | $44 | $3 |
2016: 38 drugs
| Renvela | 134 | $209,217 | $1,561 |
| Sensipar | 112 | $140,180 | $1,252 |
| Renagel | 29 | $87,953 | $3,033 |
| Velphoro | 20 | $23,016 | $1,151 |
| Prosol | 55 | $8,214 | $149 |
| Procrit | 15 | $6,429 | $429 |
| Calcium Acetate | 67 | $5,734 | $86 |
| Calcitriol | 253 | $5,391 | $21 |
| Lantus | 15 | $3,792 | $253 |
| Zetia | 13 | $3,535 | $272 |
| Sps | 16 | $2,911 | $182 |
| Potassium Citrate Er | 26 | $1,735 | $67 |
| Allopurinol | 127 | $1,624 | $13 |
| Labetalol | 31 | $1,331 | $43 |
| Metoprolol | 64 | $1,181 | $18 |
| Nifedipine Er | 18 | $1,013 | $56 |
| Lisinopril | 182 | $959 | $5 |
| Enalapril Maleate | 28 | $750 | $27 |
| Furosemide | 164 | $691 | $4 |
| Potassium Chloride | 26 | $680 | $26 |
| Hydralazine | 24 | $670 | $28 |
| Amlodipine Besylate | 134 | $593 | $4 |
| Pravastatin | 18 | $387 | $22 |
| Atorvastatin | 34 | $382 | $11 |
| Clonidine | 53 | $327 | $6 |
| Simvastatin | 47 | $306 | $7 |
| Levothyroxine | 13 | $273 | $21 |
| Metoprolol | 60 | $238 | $4 |
| Gabapentin | 39 | $219 | $6 |
| Losartan | 29 | $218 | $8 |
| Spironolactone | 18 | $200 | $11 |
| Tamsulosin | 13 | $164 | $13 |
| Levetiracetam | 12 | $121 | $10 |
| Pantoprazole | 13 | $93 | $7 |
| Hydrochlorothiazide | 14 | $90 | $6 |
| Omeprazole | 14 | $76 | $5 |
| Carvedilol | 12 | $74 | $6 |
| Glipizide | 19 | $65 | $3 |
2015: 37 drugs
| Renvela | 161 | $218,222 | $1,355 |
| Sensipar | 108 | $103,756 | $961 |
| Renagel | 21 | $47,972 | $2,284 |
| Calcium Acetate | 80 | $7,405 | $93 |
| Calcitriol | 215 | $4,820 | $22 |
| Advair Diskus | 12 | $4,810 | $401 |
| Lantus | 13 | $3,253 | $250 |
| Zetia | 11 | $2,497 | $227 |
| Valsartan | 29 | $1,596 | $55 |
| Lisinopril | 299 | $1,420 | $5 |
| Metoprolol | 62 | $1,354 | $22 |
| Hydralazine | 51 | $1,160 | $23 |
| Allopurinol | 124 | $1,151 | $9 |
| Labetalol | 26 | $1,142 | $44 |
| Potassium Citrate Er | 24 | $999 | $42 |
| Amlodipine Besylate | 167 | $837 | $5 |
| Nifedipine Er | 14 | $797 | $57 |
| Potassium Chloride | 24 | $612 | $26 |
| Enalapril Maleate | 20 | $533 | $27 |
| Pravastatin | 13 | $521 | $40 |
| Furosemide | 134 | $508 | $4 |
| Tamsulosin | 18 | $491 | $27 |
| Atorvastatin | 38 | $443 | $12 |
| Simvastatin | 66 | $433 | $7 |
| Metoprolol | 64 | $396 | $6 |
| Tacrolimus | 11 | $303 | $28 |
| Gabapentin | 62 | $293 | $5 |
| Clonidine | 47 | $245 | $5 |
| Losartan | 25 | $208 | $8 |
| Pantoprazole | 18 | $194 | $11 |
| Megestrol Acetate | 15 | $187 | $12 |
| Hydrochlorothiazide | 32 | $182 | $6 |
| Levetiracetam | 12 | $117 | $10 |
| Amitriptyline | 11 | $90 | $8 |
| Metoclopramide | 15 | $88 | $6 |
| Spironolactone | 15 | $78 | $5 |
| Glipizide | 13 | $41 | $3 |
2014: 35 drugs
| Renvela | 133 | $162,559 | $1,222 |
| Sensipar | 124 | $102,474 | $826 |
| Diovan | 28 | $9,635 | $344 |
| Calcium Acetate | 96 | $9,088 | $95 |
| Calcitriol | 292 | $6,360 | $22 |
| Zetia | 31 | $5,994 | $193 |
| Procrit | 34 | $5,667 | $167 |
| Kionex | 15 | $4,856 | $324 |
| Lantus | 18 | $4,007 | $223 |
| Lisinopril | 272 | $1,513 | $6 |
| Metoprolol | 24 | $917 | $38 |
| Hydralazine | 37 | $905 | $24 |
| Clonidine | 51 | $612 | $12 |
| Tamsulosin | 26 | $601 | $23 |
| Amlodipine Besylate | 115 | $592 | $5 |
| Allopurinol | 134 | $585 | $4 |
| Isosorbide Dinitrate | 11 | $569 | $52 |
| Pravastatin | 22 | $506 | $23 |
| Metoprolol | 59 | $502 | $9 |
| Enalapril Maleate | 43 | $494 | $11 |
| Simvastatin | 73 | $467 | $6 |
| Lidocaine-Prilocaine | 14 | $387 | $28 |
| Ropinirole | 18 | $370 | $21 |
| Furosemide | 85 | $364 | $4 |
| Potassium Citrate Er | 12 | $361 | $30 |
| Potassium Chloride | 11 | $345 | $31 |
| Levetiracetam | 22 | $328 | $15 |
| Gabapentin | 41 | $261 | $6 |
| Carvedilol | 29 | $220 | $8 |
| Pantoprazole | 25 | $195 | $8 |
| Glipizide | 22 | $177 | $8 |
| Losartan | 14 | $176 | $13 |
| Megestrol Acetate | 11 | $166 | $15 |
| Hydrochlorothiazide | 21 | $112 | $5 |
| Atenolol | 11 | $29 | $3 |
2013: 31 drugs
| Renvela | 157 | $152,641 | $972 |
| Sensipar | 59 | $49,171 | $833 |
| Diovan | 38 | $10,195 | $268 |
| Prosol | 36 | $9,319 | $259 |
| Calcium Acetate | 67 | $4,877 | $73 |
| Calcitriol | 201 | $4,158 | $21 |
| Intralipid | 15 | $3,396 | $226 |
| Zetia | 20 | $3,222 | $161 |
| Lantus | 19 | $2,981 | $157 |
| Nifedipine Er | 26 | $2,279 | $88 |
| Isosorbide Dinitrate | 13 | $2,054 | $158 |
| Potassium Citrate | 19 | $1,722 | $91 |
| Hydralazine | 48 | $1,437 | $30 |
| Lisinopril | 165 | $1,072 | $6 |
| Amlodipine Besylate | 127 | $873 | $7 |
| Lidocaine-Prilocaine | 12 | $657 | $55 |
| Metoprolol | 28 | $590 | $21 |
| Simvastatin | 69 | $579 | $8 |
| Losartan | 27 | $507 | $19 |
| Labetalol | 14 | $500 | $36 |
| Clonidine | 44 | $487 | $11 |
| Gabapentin | 68 | $455 | $7 |
| Metoprolol | 60 | $448 | $7 |
| Furosemide | 73 | $398 | $5 |
| Allopurinol | 90 | $379 | $4 |
| Pravastatin | 18 | $342 | $19 |
| Levetiracetam | 17 | $307 | $18 |
| Enalapril Maleate | 30 | $215 | $7 |
| Glipizide | 25 | $202 | $8 |
| Carvedilol | 17 | $178 | $10 |
| Ranitidine | 14 | $109 | $8 |
Money from drug and device companies
$1,154 in 2025
| 2025 | 15 | 52 | None | $1,154 |
| 2024 | 13 | 60 | None | $1,162 |
| 2023 | 9 | 34 | None | $568 |
| 2022 | 9 | 36 | None | $485 |
| 2021 | 7 | 61 | None | $703 |
| 2020 | 10 | 64 | None | $1,050 |
| 2019 | 8 | 48 | None | $581 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Fresenius USA Marketing | Velphoro | $217 | 10 payments
|
| Novartis Pharmaceuticals | Fabhalta | $163 | 7 payments
|
| Amgen | Krystexxa | $137 | 7 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $107 | 5 payments
|
| Calliditas Therapeutics US | Tarpeyo | $84 | 3 payments
|
| Novo Nordisk | Ozempic | $69 | 3 payments
|
See all 52 published payments
| Calliditas Therapeutics US | Meals · 2025-11-17 | Tarpeyo | $21 |
| Apellis Pharmaceuticals | Meals · 2025-11-04 | Empaveli | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-28 | Kerendia | $20 |
| Otsuka America Pharmaceutical | Meals · 2025-10-20 | Jynarque | $20 |
| Scpharmaceuticals | Meals · 2025-10-20 | Furoscix | $20 |
| Fresenius USA Marketing | Meals · 2025-10-20 | Velphoro | $25 |
| Scpharmaceuticals | Meals · 2025-10-15 | Furoscix | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-14 | Farxiga | $15 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-24 | Kerendia | $22 |
| Amgen | Meals · 2025-09-22 | Krystexxa | $20 |
| Fresenius USA Marketing | Meals · 2025-09-19 | Velphoro | $22 |
| Amgen | Meals · 2025-09-16 | Krystexxa | $10 |
| Lilly USA | Meals · 2025-09-11 | Jardiance | $14 |
| Novartis Pharmaceuticals | Meals · 2025-09-04 | Fabhalta | $31 |
| Ardelyx | Meals · 2025-09-02 | Ibsrela | $26 |
| Fresenius USA Marketing | Meals · 2025-08-28 | Velphoro | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-07 | Kerendia | $27 |
| Amgen | Meals · 2025-07-29 | Krystexxa | $23 |
| Novartis Pharmaceuticals | Meals · 2025-07-25 | Fabhalta | $23 |
| Calliditas Therapeutics US | Meals · 2025-07-21 | Tarpeyo | $31 |
| Amgen | Meals · 2025-07-08 | Krystexxa | $7 |
| Novartis Pharmaceuticals | Meals · 2025-06-27 | Fabhalta | $25 |
| Calliditas Therapeutics US | Meals · 2025-06-25 | Tarpeyo | $32 |
| Fresenius USA Marketing | Meals · 2025-06-23 | Velphoro | $23 |
| Novartis Pharmaceuticals | Meals · 2025-06-05 | Fabhalta | $16 |
| Fresenius USA Marketing | Meals · 2025-06-04 | Velphoro | $25 |
| Lilly USA | Meals · 2025-05-29 | Jardiance | $14 |
| Apellis Pharmaceuticals | Meals · 2025-05-27 | None | $23 |
| Novartis Pharmaceuticals | Meals · 2025-05-16 | Fabhalta | $25 |
| Travere Therapeutics | Meals · 2025-05-01 | None | $13 |
| Fresenius USA Marketing | Meals · 2025-05-01 | Velphoro | $5 |
| Travere Therapeutics | Meals · 2025-04-29 | None | $27 |
| Novo Nordisk | Meals · 2025-04-22 | Ozempic | $22 |
| Fresenius USA Marketing | Meals · 2025-04-16 | Velphoro | $26 |
| Amgen | Meals · 2025-04-04 | Tavneos | $31 |
| Fresenius USA Marketing | Meals · 2025-03-28 | Velphoro | $19 |
| Novartis Pharmaceuticals | Meals · 2025-03-24 | Fabhalta | $18 |
| Lilly USA | Meals · 2025-03-13 | Jardiance | $35 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-10 | Kerendia | $20 |
| Fresenius USA Marketing | Meals · 2025-03-10 | Velphoro | $23 |
| Amgen | Meals · 2025-03-06 | Krystexxa | $15 |
| Amgen | Meals · 2025-03-03 | Krystexxa | $31 |
| Novo Nordisk | Meals · 2025-02-28 | Ozempic | $14 |
| Novo Nordisk | Meals · 2025-02-11 | None | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-10 | Farxiga | $17 |
| Fresenius USA Marketing | Meals · 2025-02-10 | Velphoro | $23 |
| Mallinckrodt Hospital Products | Meals · 2025-02-07 | Acthar | $21 |
| OPKO Pharmaceuticals | Education · 2025-01-30 | Rayaldee | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-18 | Kerendia | $17 |
| Otsuka America Pharmaceutical | Meals · 2025-01-14 | Jynarque | $24 |
| Novartis Pharmaceuticals | Meals · 2025-01-10 | Fabhalta | $25 |
| Mallinckrodt Hospital Products | Meals · 2025-01-07 | Acthar | $36 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,162
| Novartis Pharmaceuticals | Fabhalta | $228 | 12 payments
|
| Calliditas Therapeutics US | Tarpeyo | $178 | 14 payments
|
| Amgen | Krystexxa | $173 | 8 payments
|
| Lilly USA | Jardiance | $116 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $91 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $80 | 4 payments
|
| OPKO Pharmaceuticals | Rayaldee | $56 | 3 payments
|
| GlaxoSmithKline | Jesduvroq | $55 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $53 | 2 payments
|
| Ardelyx | Ibsrela | $39 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $36 | 2 payments
|
| Travere Therapeutics | None | $32 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $24 | 1 payment
|
2023: $568
| AstraZeneca Pharmaceuticals LP | Lokelma | $133 | 5 payments
|
| Travere Therapeutics | None | $108 | 7 payments
|
| Horizon Therapeutics plc | Krystexxa | $106 | 5 payments
|
| OPKO Pharmaceuticals | Rayaldee | $69 | 3 payments
|
| GlaxoSmithKline | Jesduvroq | $63 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $30 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $23 | 1 payment
|
| Novartis Pharmaceuticals | None | $20 | 1 payment
|
| Genzyme | Fabrazyme | $15 | 1 payment
|
2022: $485
| OPKO Pharmaceuticals | Rayaldee | $148 | 19 payments
|
| Calliditas Therapeutics US | Tarpeyo | $102 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $60 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $52 | 3 payments
|
| GlaxoSmithKline | Benlysta | $42 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $24 | 1 payment
|
| Travere Therapeutics | None | $24 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $17 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $16 | 1 payment
|
2021: $703
| AstraZeneca Pharmaceuticals LP | Lokelma | $239 | 14 payments
|
| OPKO Pharmaceuticals | Rayaldee | $196 | 28 payments
|
| Mallinckrodt Hospital Products | Acthar | $135 | 11 payments
|
| Otsuka America Pharmaceutical | Jynarque | $49 | 2 payments
|
| Vifor Pharma | Veltassa | $40 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $25 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $20 | 1 payment
|
2020: $1,050
| AstraZeneca Pharmaceuticals LP | Lokelma | $456 | 16 payments
|
| OPKO Pharmaceuticals | Rayaldee | $184 | 20 payments
|
| Mallinckrodt Hospital Products | Acthar | $181 | 11 payments
|
| Relypsa | Veltassa | $88 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $37 | 2 payments
|
| Amgen | Parsabiv | $23 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $21 | 1 payment
|
| Genzyme | None | $20 | 1 payment
|
| Sanofi-Aventis U.S. | Fabrazyme | $20 | 1 payment
|
| Akebia Therapeutics | Auryxia | $20 | 1 payment
|
2019: $581
| AstraZeneca Pharmaceuticals LP | Lokelma | $179 | 9 payments
|
| OPKO Pharmaceuticals | Rayaldee | $173 | 23 payments
|
| Otsuka America Pharmaceutical | Jynarque | $134 | 7 payments
|
| Genzyme | Fabrazyme | $23 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $21 | 1 payment
|
| Relypsa | Veltassa | $20 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $18 | 1 payment
|
| Amgen | Parsabiv | $13 | 1 payment
|
Professional record
- NPI
- 1447429212
- Licence
- CA A108175, OH 57.012750California A108175: Current · expires 2027-06-30
- Group
- West Coast Kidney
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- 1999 Mowry Ave, Suite R, Fremont, CA, 94538
- NPI first listed
- 2008-02-26
- NPI last updated
- 2010-12-31
This is when the NPI record was last certified, not a medical board exam.